Larimar Therapeutics, Inc. Common Stock LRMR
i
Market datapartial · fetched 2026-11-12T01:52:16.060Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:57:40.020395656Z
FundamentalsAlpha Vantage · unavailable
Larimar Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 4.83 | 105.3% | 82.3% | |||
| 30Δ | 4.56 | 103.8% | 74.4% | 2.85 | 200.7% | 40.0% |
| 35Δ | 4.29 | 102.3% | 66.5% | 3.33 | 196.2% | 36.3% |
| 40Δ | 4.01 | 100.8% | 58.6% | 3.80 | 191.7% | 32.5% |
| 45Δ | 3.74 | 99.3% | 50.7% | 4.28 | 187.2% | 28.8% |
| 50Δ | 3.47 | 97.8% | 42.7% | 4.76 | 182.6% | 25.1% |
| 55Δ | 3.20 | 96.3% | 34.8% | 5.23 | 178.1% | 21.4% |
| 60Δ | 2.92 | 94.8% | 26.9% | 5.71 | 173.6% | 17.7% |
| 65Δ | 2.65 | 93.3% | 19.0% | 6.18 | 169.1% | 13.9% |
| 70Δ | 6.66 | 164.6% | 10.2% | |||
| 75Δ | 7.13 | 160.0% | 6.5% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.83
- IV
- 105.3%
- B/E move
- 82.3%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 4.56
- IV
- 103.8%
- B/E move
- 74.4%
- Pseudo strike
- 2.85
- IV
- 200.7%
- B/E move
- 40.0%
35Δ
- Pseudo strike
- 4.29
- IV
- 102.3%
- B/E move
- 66.5%
- Pseudo strike
- 3.33
- IV
- 196.2%
- B/E move
- 36.3%
40Δ
- Pseudo strike
- 4.01
- IV
- 100.8%
- B/E move
- 58.6%
- Pseudo strike
- 3.80
- IV
- 191.7%
- B/E move
- 32.5%
45Δ
- Pseudo strike
- 3.74
- IV
- 99.3%
- B/E move
- 50.7%
- Pseudo strike
- 4.28
- IV
- 187.2%
- B/E move
- 28.8%
50Δ
- Pseudo strike
- 3.47
- IV
- 97.8%
- B/E move
- 42.7%
- Pseudo strike
- 4.76
- IV
- 182.6%
- B/E move
- 25.1%
55Δ
- Pseudo strike
- 3.20
- IV
- 96.3%
- B/E move
- 34.8%
- Pseudo strike
- 5.23
- IV
- 178.1%
- B/E move
- 21.4%
60Δ
- Pseudo strike
- 2.92
- IV
- 94.8%
- B/E move
- 26.9%
- Pseudo strike
- 5.71
- IV
- 173.6%
- B/E move
- 17.7%
65Δ
- Pseudo strike
- 2.65
- IV
- 93.3%
- B/E move
- 19.0%
- Pseudo strike
- 6.18
- IV
- 169.1%
- B/E move
- 13.9%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.66
- IV
- 164.6%
- B/E move
- 10.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.13
- IV
- 160.0%
- B/E move
- 6.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 192.56% |
Biotechnology
LXEO
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
More →LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in…
More →LYEL
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South…
More →MANE
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New…
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →MBX
Description unavailable
More →